Why the study?
Recent evidence demonstrates good effectiveness and safety of flecainide across diverse populations, raising questions about reinterpreting CAST results and expanding its indications and clinical use in supraventricular arrhythmias.
This review provides a practical guide on the optimal clinical use, indications, and safety monitoring of flecainide for supraventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
May guide flecainide use and monitoring for SVT; leaves open need for prospective validation.
Transcatheter ablation was increasingly and successfully used to treat symptomatic drug refractory patients affected by supraventricular arrhythmias. Antiarrhythmic drug treatment still plays a major role in patient management, alone or combined with non-pharmacological therapies. Flecainide is an IC antiarrhythmic drug approved in 1984 from the Food and Drug Administration for the suppression of sustained ventricular tachycardia and later for acute cardioversion of atrial fibrillation and for sinus rhythm maintenance. Currently, flecainide is mostly used for sinus rhythm maintenance in atrial fibrillation (AF) patients without structural cardiomyopathy although recent studies enrolling different patient populations have demonstrated a good effectiveness and safety profile. How should we interpret the results of the CAST after the latest evidence? Is it possible to expand the indications of flecainide, and therefore, its use? This review aims to highlight the main characteristics of flecainide, as well as its optimal clinical use, delineating drug indications and contraindications and appropriate monitoring, based on the most recent evidence.
No takes yet. Share an insight, caveat, or question.
Lavalle et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: